

# Tuomas Mirtti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7398896/publications.pdf>

Version: 2024-02-01

74  
papers

1,420  
citations

361413  
20  
h-index

361022  
35  
g-index

78  
all docs

78  
docs citations

78  
times ranked

2986  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prospective Longitudinal Health-related Quality of Life Analysis of the Finnish Arm of the PRIAS Active Surveillance Cohort: 11 Years of Follow-up. <i>European Urology Focus</i> , 2022, 8, 1151-1156.	3.1	2
2	Detection of Prostate Cancer Using Biparametric Prostate <scp>MRI</scp>, Radiomics, and Kallikreins: A Retrospective Multicenter Study of Men With a Clinical Suspicion of Prostate Cancer. <i>Journal of Magnetic Resonance Imaging</i> , 2022, 55, 465-477.	3.4	9
3	Exploration of Extracellular Vesicle miRNAs, Targeted mRNAs and Pathways in Prostate Cancer: Relation to Disease Status and Progression. <i>Cancers</i> , 2022, 14, 532.	3.7	7
4	Increased Expression and Altered Cellular Localization of Fibroblast Growth Factor Receptor-Like 1 (FGFRL1) Are Associated with Prostate Cancer Progression. <i>Cancers</i> , 2022, 14, 278.	3.7	2
5	T and NK cell abundance defines two distinct subgroups of renal cell carcinoma. <i>OncoImmunology</i> , 2022, 11, 1993042.	4.6	16
6	Population-based randomized trial of screening for clinically significant prostate cancer ProScreen: a pilot study. <i>BJU International</i> , 2022, 130, 193-199.	2.5	13
7	Spectral decoupling for training transferable neural networks in medical imaging. <i>IScience</i> , 2022, 25, 103767.	4.1	2
8	The Movember Global Action Plan 1 (GAP1): Unique Prostate Cancer Tissue Microarray Resource. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 715-727.	2.5	0
9	Stromal FAP Expression is Associated with MRI Visibility and Patient Survival in Prostate Cancer. <i>Cancer Research Communications</i> , 2022, 2, 172-181.	1.7	2
10	AI Model for Prostate Biopsies Predicts Cancer Survival. <i>Diagnostics</i> , 2022, 12, 1031.	2.6	2
11	Abstract PR016: The spatial landscape of clonal somatic mutations in benign and malignant tissue. <i>Cancer Research</i> , 2022, 82, PR016-PR016.	0.9	0
12	Characteristics of Patients in SPCG-15 "A Randomized Trial Comparing Radical Prostatectomy with Primary Radiotherapy plus Androgen Deprivation Therapy in Men with Locally Advanced Prostate Cancer. <i>European Urology Open Science</i> , 2022, 41, 63-73.	0.4	3
13	Active surveillance versus initial surgery in the long-term management of Bosniak IIF "IV cystic renal masses. <i>Scientific Reports</i> , 2022, 12, .	3.3	5
14	Abstract 2171: The spatial landscape of clonal somatic mutations in benign and malignant tissue. <i>Cancer Research</i> , 2022, 82, 2171-2171.	0.9	0
15	Abstract 2234: Incidence of clinically significant prostate cancer after negative prostate MRI - comparison to general population. <i>Cancer Research</i> , 2022, 82, 2234-2234.	0.9	0
16	Abstract 5171: Gene expression in multi-parametric MRI visible and invisible prostate cancers predicts progression. <i>Cancer Research</i> , 2022, 82, 5171-5171.	0.9	0
17	Three-Dimensional Presentation of Tumor Histopathology: A Model Using Tongue Squamous Cell Carcinoma. <i>Diagnostics</i> , 2021, 11, 109.	2.6	6
18	Grading Evolution and Contemporary Prognostic Biomarkers of Clinically Significant Prostate Cancer. <i>Cancers</i> , 2021, 13, 628.	3.7	7

#	ARTICLE	IF	CITATIONS
19	Response to Letter on use of functional imaging by 11C-metomidate PET for primary aldosteronism subtyping. European Journal of Endocrinology, 2021, 184, L11-L12.	3.7	2
20	Transcript analysis of commercial prostate cancer risk stratification panels in hard-to-predict grade group 2-4 prostate cancers. Prostate, 2021, 81, 368-376.	2.3	6
21	Adiponectin receptor agonist AdipoRon ameliorates renal inflammation in diet-induced obese mice and endotoxin-treated human glomeruli ex vivo. Diabetologia, 2021, 64, 1866-1879.	6.3	24
22	Prognostic and predictive value of ALDH1, SOX2 and SSEA-4 in bladder cancer. Scientific Reports, 2021, 11, 13684.	3.3	3
23	Prediction of neo-adjuvant chemotherapy response in bladder cancer: the impact of clinical parameters and routine biomarkers. Scandinavian Journal of Urology, 2021, 55, 448-454.	1.0	2
24	Morphological Features Extracted by AI Associated with Spatial Transcriptomics in Prostate Cancer. Cancers, 2021, 13, 4837.	3.7	15
25	Fast prostate retrieval in robot-assisted laparoscopic prostatectomy for next-generation biobanking. Journal of Robotic Surgery, 2020, 14, 271-274.	1.8	1
26	Enzalutamide-Induced Feed-Forward Signaling Loop Promotes Therapy-Resistant Prostate Cancer Growth Providing an Exploitable Molecular Target for Jak2 Inhibitors. Molecular Cancer Therapeutics, 2020, 19, 231-246.	4.1	16
27	Qualitative and Quantitative Reporting of a Unique Biparametric MRI: Towards Biparametric MRI-Based Nomograms for Prediction of Prostate Biopsy Outcome in Men With a Clinical Suspicion of Prostate Cancer (IMPROD and MULTI-IMPROD Trials). Journal of Magnetic Resonance Imaging, 2020, 51, 1556-1567.	3.4	22
28	Cost-effective survival prediction for patients with advanced prostate cancer using clinical trial and real-world hospital registry datasets. International Journal of Medical Informatics, 2020, 133, 104014.	3.3	11
29	Expected impact of MRI-related interreader variability on ProScreen prostate cancer screening trial: a pre-trial validation study. Cancer Imaging, 2020, 20, 72.	2.8	10
30	Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition. Oncoimmunology, 2020, 9, 1761229.	4.6	22
31	PTEN and ERG expression in MRI-ultrasound guided fusion biopsy correlated with radical prostatectomy findings in men with prostate cancer. Prostate, 2020, 80, 1118-1127.	2.3	2
32	Prostate MRI added to CAPRA, MSKCC and Partin cancer nomograms significantly enhances the prediction of adverse findings and biochemical recurrence after radical prostatectomy. PLoS ONE, 2020, 15, e0235779.	2.5	8
33	Associations of PTEN and ERG with Magnetic Resonance Imaging Visibility and Assessment of Non-organ-confined Pathology and Biochemical Recurrence After Radical Prostatectomy. European Urology Focus, 2020, 7, 1316-1323.	3.1	4
34	Functional imaging with 11C-metomidate PET for subtype diagnosis in primary aldosteronism. European Journal of Endocrinology, 2020, 183, 539-550.	3.7	36
35	Title is missing!. , 2020, 15, e0235779.		0
36	Title is missing!. , 2020, 15, e0235779.		0

#	ARTICLE	IF	CITATIONS
37	Title is missing!. , 2020, 15, e0235779.		0
38	Title is missing!. , 2020, 15, e0235779.		0
39	Clonal heterogeneity influences drug responsiveness in renal cancer assessed by <i>ex vivo</i> drug testing of multiple patientâ€derived cancer cells. International Journal of Cancer, 2019, 144, 1356-1366.	5.1	29
40	Tumor expression of human chorionic gonadotropin beta mRNA and prognosis of prostate cancer treated by radical prostatectomy. Scandinavian Journal of Clinical and Laboratory Investigation, 2019, 79, 424-430.	1.2	1
41	Fibroblast as a critical stromal cell type determining prognosis in prostate cancer. Prostate, 2019, 79, 1505-1513.	2.3	23
42	Validation of IMPROD biparametric MRI in men with clinically suspected prostate cancer: A prospective multi-institutional trial. PLoS Medicine, 2019, 16, e1002813.	8.4	43
43	Positive STAT5 Protein and Locus Amplification Status Predicts Recurrence after Radical Prostatectomy to Assist Clinical Precision Management of Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1642-1651.	2.5	13
44	Metformin increases glucose uptake and acts renoprotectively by reducing SHIP2 activity. FASEB Journal, 2019, 33, 2858-2869.	0.5	59
45	The role of enzalutamide-induced hyperactive Jak2-Stat5 feed-forward signaling loop on enzalutamide-resistant prostate cancer growth and as a therapeutic target for second-line treatment.. Journal of Clinical Oncology, 2019, 37, 221-221.	1.6	2
46	New prostate cancer grade grouping system predicts survival after radical prostatectomy. Human Pathology, 2018, 75, 159-166.	2.0	17
47	ITGB1-dependent upregulation of Caveolin-1 switches TGFÎ² signalling from tumour-suppressive to oncogenic in prostate cancer. Scientific Reports, 2018, 8, 2338.	3.3	29
48	PTEN Loss but Not ERG Expression in Diagnostic Biopsies Is Associated with Increased Risk of Progression and Adverse Surgical Findings in Men with Prostate Cancer on Active Surveillance. European Urology Focus, 2018, 4, 867-873.	3.1	30
49	Feasibility of Prostate PAXgene Fixation for Molecular Research and Diagnostic Surgical Pathology. American Journal of Surgical Pathology, 2018, 42, 103-115.	3.7	14
50	SPCG-15: a prospective randomized study comparing primary radical prostatectomy and primary radiotherapy plus androgen deprivation therapy for locally advanced prostate cancer. Scandinavian Journal of Urology, 2018, 52, 313-320.	1.0	40
51	Patient Experience of Systematic Versus Fusion Prostate Biopsies. European Urology Oncology, 2018, 1, 202-207.	5.4	20
52	Cumulative Cancer Locations is a Novel Metric for Predicting Active Surveillance Outcomes: A Multicenter Study. European Urology Oncology, 2018, 1, 268-275.	5.4	5
53	Increased HSF1 expression predicts shorter disease-specific survival of prostate cancer patients following radical prostatectomy. Oncotarget, 2018, 9, 31200-31213.	1.8	19
54	Comprehensive Drug Testing of Patient-derived Conditionally Reprogrammed Cells from Castration-resistant Prostate Cancer. European Urology, 2017, 71, 319-327.	1.9	74

#	ARTICLE	IF	CITATIONS
55	Re: Fatemeh Seyednasrollah, Mehrad Mahmoudian, Liisa Rautakorpi, et al. How Reliable are Trial-based Prognostic Models in Real-world Patients with Metastatic Castration-resistant Prostate Cancer? Eur Urol. 2017;71:838â€“40. European Urology, 2017, 72, e68-e69.	1.9	0
56	Immunological tumor status may predict response to neoadjuvant chemotherapy and outcome after radical cystectomy in bladder cancer. Scientific Reports, 2017, 7, 12682.	3.3	16
57	A randomized trial of early detection of clinically significant prostate cancer (ProScreen): study design and rationale. European Journal of Epidemiology, 2017, 32, 521-527.	5.7	36
58	Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data. Lancet Oncology, The, 2017, 18, 132-142.	10.7	124
59	Metabolomic Profiling of Extracellular Vesicles and Alternative Normalization Methods Reveal Enriched Metabolites and Strategies to Study Prostate Cancer-Related Changes. Theranostics, 2017, 7, 3824-3841.	10.0	167
60	Repeat multiparametric MRI in prostate cancer patients on active surveillance. PLoS ONE, 2017, 12, e0189272.	2.5	23
61	Hypoxia Marker GLUT-1 (Glucose Transporter 1) is an Independent Prognostic Factor for Survival in Bladder Cancer Patients Treated with Radical Cystectomy. Bladder Cancer, 2016, 2, 101-109.	0.4	31
62	Benefit of Adjuvant Chemotherapy and Pelvic Lymph Node Dissection in pT3 and Node Positive Bladder Cancer Patients Treated with Radical Cystectomy. Bladder Cancer, 2016, 2, 263-272.	0.4	7
63	Increased expression of fibroblast growth factor 13 in prostate cancer is associated with shortened time to biochemical recurrence after radical prostatectomy. International Journal of Cancer, 2016, 139, 140-152.	5.1	23
64	Outcome of surgery for patients with renal cell carcinoma and tumour thrombus in the era of modern targeted therapy. Scandinavian Journal of Urology, 2016, 50, 380-386.	1.0	12
65	Loss of PTEN expression in ERG-negative prostate cancer predicts secondary therapies and leads to shorter disease-specific survival time after radical prostatectomy. Modern Pathology, 2016, 29, 1565-1574.	5.5	43
66	Longitudinal modeling of ultrasensitive and traditional prostate-specific antigen and prediction of biochemical recurrence after radical prostatectomy. Scientific Reports, 2016, 6, 36161.	3.3	3
67	Association of Angiopoietin-2 and Ki-67 Expression with Vascular Density and Sunitinib Response in Metastatic Renal Cell Carcinoma. PLoS ONE, 2016, 11, e0153745.	2.5	20
68	Tumor-Associated Macrophages Provide Significant Prognostic Information in Urothelial Bladder Cancer. PLoS ONE, 2015, 10, e0133552.	2.5	55
69	Role of ultrasensitive prostate-specific antigen in the follow-up of prostate cancer after radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 16.e1-16.e7.	1.6	5
70	Inhibition of Stat5a/b Enhances Proteasomal Degradation of Androgen Receptor Liganded by Antiandrogens in Prostate Cancer. Molecular Cancer Therapeutics, 2015, 14, 713-726.	4.1	16
71	Rac1 Nucleocytoplasmic Shuttling Drives Nuclear Shape Changes and Tumor Invasion. Developmental Cell, 2015, 32, 318-334.	7.0	75
72	Differential Predictive Roles of A- and B-Type Nuclear Lamins in Prostate Cancer Progression. PLoS ONE, 2015, 10, e0140671.	2.5	39

#	ARTICLE	IF	CITATIONS
73	Correlation of endothelial angiopoietin-2 expression with tumor angiogenesis and response to sunitinib in metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2015, 33, 461-461.	1.6	0
74	Nuclear Stat5a/b predicts early recurrence and prostate cancerâ€specific death in patients treated by radical prostatectomy. Human Pathology, 2013, 44, 310-319.	2.0	42